Drugs Made In America Acquisition Corp. Units
NASDAQ: DMAAU0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Financial Services
- Industry
- Financial - Conglomerates
- CEO
- Roger Bendelac
- Employees
- 2
- Headquarters
- Fort Lauderdale, United States
- IPO year
- 2025
- Market cap
- $369.2M
- Website
- https://dmaacorp.com
Loading DMAAU…
Loading profile data…Frequently asked questions about DMAAU
What does Drugs Made In America Acquisition Corp. Units (DMAAU) do?
Drugs Made In America Acquisition Corp. operates as a special purpose acquisition company (SPAC). Its primary objective is to achieve a business combination, which may involve a merger, an asset acquisition, a share exchange, or a corporate restructuring, with one or more existing enterprises. The firm was established on May 23, 2024, and mainta...
Where does DMAAU trade?
Drugs Made In America Acquisition Corp. Units (DMAAU) trades on the NASDAQ Global Market.
What sector is DMAAU in?
Drugs Made In America Acquisition Corp. Units (DMAAU) operates in the Financial Services sector, specifically in the Financial - Conglomerates industry.
Who is the CEO of Drugs Made In America Acquisition Corp. Units?
Roger Bendelac is the chief executive officer of Drugs Made In America Acquisition Corp. Units (DMAAU).
Where is Drugs Made In America Acquisition Corp. Units headquartered?
Drugs Made In America Acquisition Corp. Units is headquartered in United States.
Does DMAAU pay a dividend?
Drugs Made In America Acquisition Corp. Units (DMAAU) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DMAAU go public?
Drugs Made In America Acquisition Corp. Units (DMAAU) completed its initial public offering in 2025.